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Background: The association between diabetes and chronic liver disease has been well documented. 
However, the mechanism remains unknown. The aim of this study was to investigate the insulin resistance in 
chronic liver disease and normal liver in diabetic patient.  
Method: A total of 31 diabetic, non-alcoholic patients with multiple oral hypoglycemic drugs, either 
with or without lipid abnormalities were enrolled in this study. Subjects were recruited from outpatient 
clinic of Department of Endocrine at Dr. Sardjito Hospital, Jogjakarta, Indonesia from May-June 2004. 
This was a cross sectional study. Fasting insulin and glucose level, liver function test, body mass index, 
and the presence of fatty liver by ultrasound were examined. Insulin resistance was estimated by 
calculating fasting insulin and glucose plasma level as the homeostasis model assessment (HOMA) index 
ratio. Data was described with mean ± SD and analyzed by independent sample t-test. 
Results: Thirty one patients were enrolled to the study, i.e. 8 patients with normal liver and 23 patients 
with fatty liver. Only 14 patients agreed to continue the study including 10 patients with fatty liver and 
4 patients with normal liver. Mean of age was 59.1 ± 8.7 and mean value of BMI was 24.62 ± 3.05. 
The liver function test revealed normal results. Triglyceride, cholesterol, fasting glucose level, and HOMA 
index (2.77 ± 1.95 vs. 1.66 ± 1.02) in patients with fatty liver were  higher than patients with normal liver. 
No correlation was found between fasting insulin level as well as HOMA index and mean value of BMI 
(obese and non-obese) as well as hypertension. There was significant correlation between triglyceride 
level and fasting insulin among fatty liver patients (p = 0.048; CI 95% -7.404; -0.032). 
Conclusion: The non-alcoholic fatty liver disease in diabetic patients with normal liver enzymes and 
multiple oral hypoglycemic drugs appear to be related with insulin resistance and hypertriglyceridemia. 
 




Until now, the pathogenesis and therapy for patients  
with insulin resistance still remains unclear.1,2 Yet, such  
patients have a long term risk of developing fatty liver  
and turn to liver cancer (hepatocellular carcinoma).3,4  
The liver of a patient with diabetes mellitus has  
a growing risk to become non-alcoholic fatty liver  
disease (NAFLD), including   severe non-alcoholic 
steatohepatitis (NASH), which eventually will lead to 
liver fibrosis, cirrhosis, and 8-30% will develop into liver 
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The association between diabetes mellitus and liver 
disease has remained uncertain whether it is caused  
by glucose intolerance or by the diabetes.4,5  
The pathophysiology of NAFLD also has not been fairly  
understood,6 and the pathophysiology which still taken  
now is the multiple-hit hypothesis which is divided  
into 2 stages, i.e. stage 1 (one) a condition with insulin  
resistance and obesity which may cause steatosis  
development; and stage 2 (two) is the presence of 
oxidative stress which activates inflammatory response  
and develop into NASH. Completing stage 2, there are  
more stages that possibly follow due to the leptin  
effect which may promote insulin resistance, oxidative  
stress, or secretion of cytokines. The insulin resistance  
with or without NAFLD or DM type 2 will increase 
the risk of NASH and liver fibrosis and often it will 
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This study is a preliminary study to find insulin 
resistance in patients with diabetes mellitus type 2 with or 
without chronic liver disease, as one of markers for the 
development of diabetes into NAFLD. 
 
METHODS 
The study subjects were 31 non-alcoholic patients 
with diabetes mellitus type 2, who had multiple oral 
hypoglycemic drug therapy, with or without serum lipid  
abnormalities. Subjects were recruited from outpatient  
clinic of Endocrine Division at Sardjito hospital,  
Jogjakarta, Indonesia.  The study was a cross-sectional  
study conducted in 2 months period (May-June 2004).  
All patients had examinations on fasting glucose and  
insulin level, lipid profile (cholesterol and triglycerides 
normal. Such data shows a higher number of 
hypertension, dyslipidemia, and obesity in patients with 
fatty liver than non-fatty liver. While insulin resistance 
was found more frequent in patients with fatty liver 
than the non-fatty liver. However, it has not generally 
showed a higher number of insulin resistance. 
The association between HOMA index, insulin level, 
cholesterol level, and triglyceride level in subjects with 
fatty liver are shown on table 3. It demonstrates 
a significant correlation between fasting insulin level 
and triglyceride level (p = 0.048; 95% CI = -7.404; 
-0.032). 
Table 1. Baseline characteristics 
level), alanine  transferase (ALT)  and  alkali 
phosphatase (ALP) enzymes level as well as their 
measurements on body mass index. Insulin resistance 
Variable Mean ± SD Non fatty liver Fatty liver 
Age (year) 57.91 ± 8.7 
History of diabetes 8.54 ± 5.3 
mellitus (year) 
Body mass index 24.62 ± 3.05  
was estimated by using HOMA index [fasting insulin Fasting glucose level 8.20 ± 2.88 6.89 ± 3.96 8.56 ± 2.64 
serum level (ì U/mL) x fasting glucose plasma level (mmol/L) 
(mmol/L)/22.5]. HOMA score > 2.77 was categorized 
as insulin resistance.8,9 
Fasting insulin 7.48 ± 4.37 8.13 ± 8.70 7.30 ± 3.08 
(µU/mL) 
ALT (IU/L) 35.50 ± 28.03 
ALP (IU/L) 80.00 ± 30.47 
The livers of all patients were examined by 
ultrasonograph to determine whether there is a 
feature of fatty liver and the patients had fasting 
condition for at least 5 hour earlier. The ultrasound 
diagnosis for the fatty liver was shown by bright liver 
manifestation (liver echo-structure was rougher than 
right kidney echo-structure), and NASH diagnosis was  
suspected if the ALT and ALP level > 2 times of upper  
normal limit).7All data were analyzed by SPSS version 
11.0 with t-test for independent sample. 
 
RESULTS 
There were 31 patients enrolled in this study; i.e. 
8 patients with normal liver, and 21 patients with fatty 
liver manifestation. However, only 14 patients agreed to 
continue the study, including 10 (78.6%) patients with 
fatty liver and 4 (21.4%) patients with normal liver. 
Baseline characteristics of the 14 patients are shown 
in table 1. 
Table 1 shows no increasing mean value of ALT or 
ALP level. However, there is an increase of 
triglycerides and cholesterol level in subjects with fatty 
lever. Data was not analyzed by t-test since each group 
has different number of samples. 
The subjects also had concomitant disease other  
than DM type 2, including hypertension, dyslipidemia  
and obesity (metabolic syndrome). Table 2 shows 
a hypertension value on 57.1%, hypercholesterolemia 
71.4%, hypertriglyceridemia 57.1%, mixed hyper- 
cholesterolemia and  triglyceridemia 35.7%. 
For obesity was only 42.9% and the rest was 71.4% 
normal. The insulin resistance estimated by HOMA  
index was 42.9% and the remained was 57.1% 
Triglyceride (mg/dL) 172.43 ± 75.97 133.33 ± 93.57 183.09 ± 71.8 8 
Cholesterol (mg/dL) 228.86 ± 59.13 189.00 ± 47.79 239.73 ± 59.0 0 
Liver USG 4 (21.4%) 10 (78.6%) 
Sex 
Male 5 (35.7%) 
Female 9 (64.3%) 
Normal value: fasting glucose 4.2-6.4 mmol/L; ALT 0-35 
IU/L ; ALP 30-120 IU/L; triglycerides <160 mg/dL; 
cholesterol < 200 mg/dL 
 
Table 3. Association between HOMA index, fasting insulin level, 
fasting glucose level and lipid profile in subjects with fatty liver 
Association Association significance 
HOMA - BMI p = 0.320 95% CI -1.091 ; 2.992 
HOMA - cholesterol p = 1.187 95% CI -0.900 ; 3.974 
HOMA - triglycerides p = 0.129 95% CI -3.266 ; 0.496 
Fasting insulin - BMI p = 0.541 95% CI -3.259 ; 5.802 
Fasting insulin - cholesterol p = 0.142 95% CI -1.475 ; 8.708 
Fasting insulin - triglyceride p = 0.048 95% CI -7.404 ; -0.032  
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Table 2. Concomitant disease of diabetes mellitus, BMI and HOMA index  
Variable Percentage   Fatty liver Non fatty liver 
Concomitant disease    
 Hypertension 57.1% (8) 6 2 
 Dyslipidemia    
   hypercholesterol 71.4% (10) 9 1 
   hypertriglycerides 57.1% (8) 7 1 
   mixed 35.7% (5) 5 0 
BMI    
 Overweight (> 25) 42.9% (6) 6 0 
 Normal (< 25) 71.4% (8) 4 4 
HOMA index    
 Insulin resistance (> 2.77) 42.9% (6) 5 1 
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DISCUSSION 
In this study, the mean of age is 57.91 ± 8.7 years,  
64.3% subjects are female with hypertriglyceridemia  
level of 228.86 ± 59.13 mg/dL, but most ALT and ALP  
level are normal and there is only 42.9% subjects with  
overweight BMI. Half of subjects (57.1%) have 
hypertension, a condition which is more frequent in the  
fatty liver group compared to the non-fatty liver group.  
Characteristic of patients with NAFLD are middle age,  
female with truncal obesity and hypertriglyceridemia.6  
Insulin resistance, hypertension and slight elevation of  
transamiase and alkali phosphatase enzymes are  
independent predictor for NASH and chronic liver  
disease. Insulin resistance not only has a role in lipid  
accumulation process in the liver but also in inflamma- 
tion and necrosis of liver cells, which are in  
accordance with pathogenesis of NASH.4,6,7 In  
diabetic patients, NAFLD is strongly correlated to  
insulin resistance as demonstrated by increased  
fasting insulin level in patients with NAFLD.8,10 High  
prevalence of NAFLD in non-obese hypertension  
patients with normal transaminase enzyme level seems  
to be associated with increased insulin resistance.11  
 There is no significant difference of HOMA index  
in both groups, which demonstrates that insulin  
resistance does not appear in all subjects with bright  
liver ultrasonographic features. In this study, no liver  
biopsy was performed by investigator in all patients  
since liver biopsy is an invasive method and not all  
patients gave their consent for such treatment. Some  
investigators suggest liver biopsy to determine  
diagnosis and prognosis.6,7 However,  other 
investigators indicate that routine liver biopsy in  
patient with suspected NAFLD is still controversial  
considering biopsy cost and the risk. Biopsy itself can  
not be used to evaluate the effectiveness of therapy.  
Nevertheless, in general, the prognosis of NAFLD is  
good.7 
This study is a preliminary study with a minimum 
number of subjects and was conducted in a short 
period. Based on minimal sample estimation for cross 
sectional study design, minimum number of subjects 
for this study is 96 subjects. As in fact, the prevalence 
of patients with DM type 2 is more frequent in 
population with mild/moderate obesity.12 Therefore,  
further study in population with risk is necessary.  
We should also consider the possibility of increased  
prevalence of metabolic syndrome since the  
increasing level in obesity, hypertension, dyslipidemia,  




This study shows that non-alcoholic fatty liver  
disease in patients with diabetes mellitus who have been 
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treated by multiple oral hypoglycemic drug therapy has 
demonstrated a normal level of transaminase enzymes.  
Metabolic syndrome (insulin resistance, dyslipidemia,  
obesity and hypertension) occur in some subjects.  
Insulin resistance and hypertriglyceridemia may have  
a role on NAFLD development in diabetic patients. 
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